Compare Gilead Sciences, Inc. (GILD) vs Old Dominion Freight Line Inc (ODFL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Old Dominion Freight Line Inc — how do they compare? Gilead Sciences, Inc. trades at $146.25 (market cap $182.40B), while Old Dominion Freight Line Inc trades at $181.96 (market cap $37.68B). The key difference: Gilead Sciences, Inc. is far larger — about 4.8× Old Dominion Freight Line Inc's market cap, and Gilead Sciences, Inc. pays the higher dividend (2.23%). Which is the better fit depends on your goals — on Pluang, investors hold Gilead Sciences, Inc. for 111 Days and Old Dominion Freight Line Inc for 76 Days on average.
| GILD | ODFL | |
|---|---|---|
Market Cap | $182.40B | $37.68B |
Volume | 4,469,821 | 1,550,104 |
Sector | Health | Industrials |
52-Week High | $155.80 | $248.73 |
52-Week Low | $116.74 | $126.29 |
Typical Hold Time | 111 Days | 76 Days |
Enterprise Value | $205.46B | $37.42B |
Dividend Yield | 2.23% | 0.64% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $146.85, up 1.82% today, with a bullish technical signal from moving averages and recent earnings beats in Q4 2025 and Q1 2026. The company reported strong 2025 revenue of $29.44B and net income of $8.51B, though 2026 projections show a net loss. Key developments include a partnership with PAHO to expand HIV prevention drug access in Latin America, supporting long-term growth prospects amid mixed profitability metrics.
The outlook for GILD is cautiously optimistic, driven by analyst consensus favoring a buy rating (65.52%) and a price target of $151.57. Opportunities lie in HIV and oncology pipeline advancements, but risks include negative 2026 profit margins and high debt levels. Investors should weigh strong cash flow from operations against execution risks in a competitive biopharma landscape.
ODFL trades at $175.61, down 1.35% on the day, with a bearish technical signal but strong fundamentals including a 19.44% net income margin and consistent earnings beats. The company recently announced a 4.9% general rate increase effective October 5, 2026, to offset rising costs and support service investments. Despite a high P/E ratio of 34.95, robust profitability and positive cash flow trends underpin the stock's valuation.
The outlook is mixed: analyst consensus is a buy with a $230.93 price target, implying significant upside, but near-term technical pressure and valuation concerns present risks. Key catalysts include execution of the rate increase and Q3 2026 earnings, while macroeconomic pressures on freight demand remain a headwind.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Old Dominion Freight Line Inc
Old Dominion Freight Line is the fourth-largest less-than-truckload carrier in the United States, with more than 240 service centers and 9,200-plus tractors. OD is by far one of the most disciplined and efficient providers in the trucking industry, and its profitability and capital returns stand head and shoulders above its peers. Strategic initiatives revolve around increasing network density through market share gains and maintaining industry-leading service via consistent infrastructure investment.
Read more on ODFL →
